TEVA · Teva announced a license and commercialization agreement with Samsung…

Teva announced a license and commercialization agreement with Samsung Bioepis for two FDA-approved immunology biosimilars: ETICOVO (etanercept-ykro, biosimilar to Enbrel) and infliximab-abda (biosimilar to Remicade). Teva will obtain U.S. commercialization rights for ETICOVO upon closing (expected by end of 2026) and for infliximab-abda in Q3 2027. The deal expands Teva's biosimilar portfolio under its Pivot to Growth strategy, with an upfront payment over 3 years, potential launch and sales milestones, and profit sharing.

• Teva obtains U.S. commercialization rights for two FDA-approved immunology biosimilars: ETICOVO (etanercept-ykro) and infliximab-abda.
• ETICOVO rights transfer at closing (expected by end of 2026); infliximab-abda rights transfer in Q3 2027.
• Samsung Bioepis remains responsible for regulatory oversight and manufacturing of both products.
• Teva will pay an upfront payment over 3 years; Samsung Bioepis eligible for additional launch and sales milestone payments.